The 2-loop MSSM finite temperature effective potential with stop condensation

We calculate the finite temperature 2-loop effective potential in the MSSM with stop condensation, using a 3-dimensional effective theory. We find that in a part of the parameter space, a two-stage electroweak phase transition appears possible. The first stage would be the formation of a stop condensate, and the second stage is the transition to the standard electroweak minimum. The two-stage transition could significantly relax the baryon erasure bounds, but the parameter space allowing it (m_H \lsim 100 GeV, m_tR \sim 155-160 GeV) is not very large. We estimate the reliability of our results using renormalization scale and gauge dependence. Finally we discuss some real-time aspects relevant for the viability of the two-stage scenario.Comment: 30 pages, 7 figure

Pathologies of Quenched Lattice QCD at non--zero Density and its Effective Potential

We simulate lattice QCD at non--zero baryon density and zero temperature in the quenched approximation, both in the scaling region and in the infinite coupling limit. We investigate the nature of the forbidden region -- the range of chemical potential where the simulations grow prohibitively expensive, and the results, when available, are puzzling if not unphysical. At weak coupling we have explored the sensitivity of these pathologies to the lattice size, and found that using a large lattice ($64 \times 16^3$) does not remove them. The effective potential sheds considerable light on the problems in the simulations, and gives a clear interpretation of the forbidden region. The strong coupling simulations were particularly illuminating on this point.Comment: 49 pages, uu-encoded expanding to postscript;also available at ftp://hlrz36.hlrz.kfa-juelich.de/pub/mpl/hlrz72_95.p

On One-Loop Gap Equations for the Magnetic Mass in d=3 Gauge Theory

Recently several workers have attempted determinations of the so-called magnetic mass of d=3 non-Abelian gauge theories through a one-loop gap equation, using a free massive propagator as input. Self-consistency is attained only on-shell, because the usual Feynman-graph construction is gauge-dependent off-shell. We examine two previous studies of the pinch technique proper self-energy, which is gauge-invariant at all momenta, using a free propagator as input, and show that it leads to inconsistent and unphysical result. In one case the residue of the pole has the wrong sign (necessarily implying the presence of a tachyonic pole); in the second case the residue is positive, but two orders of magnitude larger than the input residue, which shows that the residue is on the verge of becoming ghostlike. This happens because of the infrared instability of d=3 gauge theory. A possible alternative one-loop determination via the effective action also fails. The lesson is that gap equations must be considered at least at two-loop level.Comment: 21 pages, LaTex, 2 .eps figure

Speculations on Primordial Magnetic Helicity

We speculate that above or just below the electroweak phase transition magnetic fields are generated which have a net helicity (otherwise said, a Chern-Simons term) of order of magnitude $N_B + N_L$, where $N_{B,L}$ is the baryon or lepton number today. (To be more precise requires much more knowledge of B,L-generating mechanisms than we currently have.) Electromagnetic helicity generation is associated (indirectly) with the generation of electroweak Chern-Simons number through B+L anomalies. This helicity, which in the early universe is some 30 orders of magnitude greater than what would be expected from fluctuations alone in the absence of B+L violation, should be reasonably well-conserved through the evolution of the universe to around the times of matter dominance and decoupling, because the early universe is an excellent conductor. Possible consequences include early structure formation; macroscopic manifestations of CP violation in the cosmic magnetic field (measurable at least in principle, if not in practice); and an inverse-cascade dynamo mechanism in which magnetic fields and helicity are unstable to transfer to larger and larger spatial scales. We give a quasi-linear treatment of the general-relativistic MHD inverse cascade instability, finding substantial growth for helicity of the assumed magnitude out to scales $\sim l_M\epsilon^{-1}$, where $\epsilon$ is roughly the B+L to photon ratio and $l_M$ is the magnetic correlation length. We also elaborate further on an earlier proposal of the author for generation of magnetic fields above the EW phase transition.Comment: Latex, 23 page

Matrix-Applied Characterized Autologous Cultured Chondrocytes Versus Microfracture Five-Year Follow-up of a Prospective Randomized Trial

Background: Matrix-based cell therapy improves surgical handling, increases patient comfort, and allows for expanded indications with better reliability within the knee joint. Five-year efficacy and safety of autologous cultured chondrocytes on porcine collagen membrane (MACI) versus microfracture for treating cartilage defects have not yet been reported from any randomized controlled clinical trial. Purpose: To examine the clinical efficacy and safety results at 5 years after treatment with MACI and compare these with the efficacy and safety of microfracture treatment for symptomatic cartilage defects of the knee. Study Design: Randomized controlled trial; Level of evidence, 1. Methods: This article describes the 5-year follow-up of the SUMMIT (Superiority of MACI Implant Versus Microfracture Treatment) clinical trial conducted at 14 study sites in Europe. All 144 patients who participated in SUMMIT were eligible to enroll; analyses of the 5-year data were performed with data from patients who signed informed consent and continued in the Extension study. Results: Of the 144 patients randomized in the SUMMIT trial, 128 signed informed consent and continued observation in the Extension study: 65 MACI (90.3%) and 63 microfracture (87.5%). The improvements in Knee injury and Osteoarthritis Outcome Score (KOOS) Pain and Function domains previously described were maintained over the 5-year follow-up. Five years after treatment, the improvement in MACI over microfracture in the co-primary endpoint of KOOS pain and function was maintained and was clinically and statistically significant (P = .022). Improvements in activities of daily living remained statistically significantly better (P = .007) in MACI patients, with quality of life and other symptoms remaining numerically higher in MACI patients but losing statistical significance relative to the results of the SUMMIT 2-year analysis. Magnetic resonance imaging (MRI) evaluation of structural repair was performed in 120 patients at year 5. As in the 2-year SUMMIT (MACI00206) results, the MRI evaluation showed improvement in defect filling for both treatments; however, no statistically significant differences were noted between treatment groups. Conclusion: Symptomatic cartilage knee defects 3 cm2 or larger treated with MACI were clinically and statistically significantly improved at 5 years compared with microfracture treatment. No remarkable adverse events or safety issues were noted in this heterogeneous patient population. Keyword

Matrix-Applied Characterized Autologous Cultured Chondrocytes Versus Microfracture: Five-Year Follow-up of a Prospective Randomized Trial

Background: Matrix-based cell therapy improves surgical handling, increases patient comfort, and allows for expanded indications with better reliability within the knee joint. Five-year efficacy and safety of autologous cultured chondrocytes on porcine collagen membrane (MACI) versus microfracture for treating cartilage defects have not yet been reported from any randomized controlled clinical trial. Purpose: To examine the clinical efficacy and safety results at 5 years after treatment with MACI and compare these with the efficacy and safety of microfracture treatment for symptomatic cartilage defects of the knee. Study Design: Randomized controlled trial; Level of evidence, 1. Methods: This article describes the 5-year follow-up of the SUMMIT (Superiority of MACI Implant Versus Microfracture Treatment) clinical trial conducted at 14 study sites in Europe. All 144 patients who participated in SUMMIT were eligible to enroll; analyses of the 5-year data were performed with data from patients who signed informed consent and continued in the Extension study. Results: Of the 144 patients randomized in the SUMMIT trial, 128 signed informed consent and continued observation in the Extension study: 65 MACI (90.3%) and 63 microfracture (87.5%). The improvements in Knee injury and Osteoarthritis Outcome Score (KOOS) Pain and Function domains previously described were maintained over the 5-year follow-up. Five years after treatment, the improvement in MACI over microfracture in the co-primary endpoint of KOOS pain and function was maintained and was clinically and statistically significant (P = .022). Improvements in activities of daily living remained statistically significantly better (P = .007) in MACI patients, with quality of life and other symptoms remaining numerically higher in MACI patients but losing statistical significance relative to the results of the SUMMIT 2-year analysis. Magnetic resonance imaging (MRI) evaluation of structural repair was performed in 120 patients at year 5. As in the 2-year SUMMIT (MACI00206) results, the MRI evaluation showed improvement in defect filling for both treatments; however, no statistically significant differences were noted between treatment groups. Conclusion: Symptomatic cartilage knee defects 3 cm2 or larger treated with MACI were clinically and statistically significantly improved at 5 years compared with microfracture treatment. No remarkable adverse events or safety issues were noted in this heterogeneous patient population. Keyword